Viyash Scientific Ltd Upgrades Quality Grade Amid Mixed Fundamental Trends

Quality Grade Upgrade: What It Signifies

The recent upgrade in Viyash Scientific’s quality grade to average marks a significant turnaround in the company’s operational and financial metrics. This change is underpinned by a combination of improved profitability ratios, better capital efficiency, and a more manageable debt profile. While the company remains a small-cap player with a Mojo Score of 67.0 and a Hold rating, the upgrade from a previous Sell rating indicates growing investor confidence in its fundamentals.

Profitability and Returns: ROE and ROCE Trends

Return on equity (ROE) and return on capital employed (ROCE) are critical indicators of a company’s ability to generate profits from shareholders’ equity and total capital respectively. Viyash Scientific’s average ROE stands at 4.59%, while its average ROCE is 6.09%. Although these figures remain modest compared to some peers in the Pharmaceuticals & Biotechnology sector—such as Gland Pharma and Emcure Pharma, both graded as Good—the upward trend from previous periods has contributed to the quality grade improvement.

These returns, while not yet industry-leading, suggest that the company is beginning to leverage its capital more effectively. The ROCE figure, in particular, indicates a better utilisation of capital employed in the business, which is crucial for sustaining long-term growth in a capital-intensive sector like pharmaceuticals.

Growth Metrics: Sales and EBIT Expansion

Viyash Scientific has demonstrated robust growth over the past five years, with sales growing at an average annual rate of 20.85% and EBIT expanding even faster at 28.24%. This strong earnings before interest and tax growth outpaces sales growth, signalling improving operational efficiency and margin expansion. Such growth rates are encouraging for investors seeking companies with scalable business models and the ability to enhance profitability over time.

Debt and Interest Coverage: Managing Financial Risk

Debt levels have historically been a concern for Viyash Scientific, with an average debt to EBITDA ratio of 9.68 indicating relatively high leverage. However, the company’s average net debt to equity ratio of 0.46 suggests a moderate level of gearing, which is manageable within the context of its industry. Importantly, the EBIT to interest coverage ratio averages 2.30, signalling that earnings comfortably cover interest expenses by more than twice, reducing the risk of financial distress.

This improvement in interest coverage is a positive sign, reflecting stronger earnings and better cash flow management. It also supports the company’s ability to service debt without compromising operational investments or shareholder returns.

Capital Efficiency and Taxation

Sales to capital employed ratio, averaging 1.37, indicates that Viyash Scientific generates ₹1.37 in sales for every ₹1 of capital employed. While this is a reasonable figure, it lags behind some of its better-rated peers, suggesting room for improvement in asset utilisation. The company’s tax ratio stands at 35.34%, which is consistent with prevailing corporate tax rates and does not present any unusual tax burden or advantage.

Shareholding and Market Position

Institutional holding in Viyash Scientific is relatively low at 8.26%, reflecting limited institutional interest compared to larger pharmaceutical companies. Notably, the company has zero pledged shares, which is a positive indicator of shareholder confidence and reduces the risk of forced selling. The stock’s recent price movement shows a modest day change of 0.57%, with a current price of ₹262.95, trading near its 52-week high of ₹297.90, signalling some market optimism.

Comparative Performance and Sector Context

When compared to its sector peers, Viyash Scientific’s quality grade of average places it below companies like Gland Pharma, Emcure Pharma, and Sai Life Sciences, all graded Good. However, it fares better than Piramal Pharma, which is rated below average. This relative positioning highlights the company’s ongoing efforts to strengthen its fundamentals but also underscores the competitive challenges it faces within the Pharmaceuticals & Biotechnology sector.

In terms of stock returns, Viyash Scientific has outperformed the Sensex significantly over the medium term. The stock has delivered a 50.90% return over the past year and an impressive 186.97% over three years, compared to the Sensex’s negative 2.83% and positive 19.36% respectively. This outperformance reflects the market’s recognition of the company’s growth potential despite its small-cap status and quality grade constraints.

Outlook and Investor Considerations

Viyash Scientific’s upgrade to an average quality grade and Hold rating reflects a company in transition, improving its core financial metrics while still facing challenges typical of small-cap pharmaceutical firms. Investors should note the company’s strong sales and EBIT growth, improving interest coverage, and moderate leverage as positive signals. However, relatively low ROE and ROCE compared to sector leaders suggest that operational efficiency and capital utilisation need further enhancement to sustain long-term value creation.

Given the company’s recent stock performance, trading near its 52-week high, and its outperformance relative to the Sensex over multiple time horizons, Viyash Scientific remains an intriguing proposition for investors with a higher risk appetite seeking exposure to the pharmaceuticals sector’s growth potential. Nonetheless, cautious investors may prefer to monitor further improvements in profitability and capital efficiency before committing significant capital.

Overall, the company’s fundamentals have improved sufficiently to warrant a reassessment from Sell to Hold, signalling a stabilising business profile with potential for further progress.

Summary of Key Financial Metrics

To recap, Viyash Scientific’s key averages over recent years include:

• Sales Growth (5 years): 20.85%
• EBIT Growth (5 years): 28.24%
• EBIT to Interest Coverage: 2.30 times
• Debt to EBITDA: 9.68 times
• Net Debt to Equity: 0.46
• Sales to Capital Employed: 1.37
• Tax Ratio: 35.34%
• ROCE: 6.09%
• ROE: 4.59%
• Pledged Shares: 0.00%
• Institutional Holding: 8.26%

These figures collectively underpin the company’s upgraded quality grade and improved market perception.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today